251579-55-2
Chemical Structure
ABT-510
- CAS No.: 251579-55-2
- Formula:C46H83N13O11
- Molecular Weight:994.23
IUPAC Name: (S)-N-ethyl-1-(((S)-2-((2S,3R)-3-hydroxy-2-((2R,3S)-3-methyl-2-((S)-3-methyl-2-(2-(2-(N-methylacetamido)acetamido)acetamido)butanamido)pentanamido)butanamido)pentanoyl)-L-isoleucyl-L-arginyl)pyrrolidine-2-carboxamide
InChIKey: RIWLPSIAFBLILR-WVNGMBSFSA-N
SMILES: CC(N(C)CC(NCC(N[C@@H](C(C)C)C(N[C@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(NCC)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ABT-510 | 99.87% | ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Greenaway J, et al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009 Jan;8(1):64-74. [Content Brief]
- [2]. Punekar S, et al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008;75(1):9-21. [Content Brief]
